Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Spinnaker Opportunities Plc LSE:SOP London Ordinary Share GB00BYQCS703 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.65 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.0 -0.4 -1.2 - 1

Kanabo Group PLC Placing, Investment & MoU with Hellenic Dynamics

24/05/2021 7:00am

UK Regulatory (RNS & others)


Spinnaker Opportunities (LSE:SOP)
Historical Stock Chart


From Apr 2021 to Jul 2021

Click Here for more Spinnaker Opportunities Charts.

TIDMKNB

RNS Number : 5106Z

Kanabo Group PLC

24 May 2021

24 May 2021

Kanabo Group Plc

("Kanabo" or "the Company")

GBP1 million Premium Placing,

Pre-IPO Investment and a Strategic MoU Partnership

with Hellenic Dynamics S.A.

Highlights

   --   Placing to raise GBP1 million at an issue price of 22 pence per share (the "Placing Price") 

-- Placing Price represents a 10 per cent. premium to the closing mid-price of the Company's ordinary shares on 20 May 2021.

-- Pre-IPO acquisition of interest over GBP750,000 worth of shares in Hellenic Dynamics S.A ("Hellenic" or "Hellenic Dynamics"), a medical cannabis cultivator seeking a near-term listing on the London Stock Exchange;

-- The investment is part of a wider strategic partnership between the Company and Hellenic Dynamics S.A.

Details

Kanabo Group Plc (LSE:KNB) announces today that it has raised gross proceeds of GBP1million through the placing of 4,545,454 Ordinary Shares (the "Placing") at a price of 22 pence per share ("Placing Price") with a range of new and existing investors. The Placing Price represents a 10 per cent. premium to the closing mid-price of the Company's ordinary shares on 20 May 2021 and a 3.45 per cent discount to the 30-day volume weighted average price (VWAP) of 22.8 pence per Ordinary Share

Peterhouse Capital has acted as sole corporate broker to the Placing.

Additionally, Kanabo announces the signing of a Memorandum of Understanding with Hellenic Dynamics S.A. ("Hellenic Dynamics"), a medical cannabis cultivation company, in order to evaluate a potential off-take agreement. Hellenic Dynamics is a medical cannabis cultivation company with a substantial cultivation facility in Northern Greece, whose intention is to grow genetically unique strains of dried medical cannabis flowers. Under the terms of the MoU, it is envisaged that Kanabo will purchase up to 1000 kg per year EU GMP certified cannabis flowers with pre-defined THC or CBD contents, subject to certain regulatory approvals, for subsequent extraction of medical standard oils. The price for the goods will be negotiated between the buyer and the seller based on the specifications, products and quantities required at commercially attractive rates having regard to market prices at the time of sale.

In order to cement the relationship between Kanabo and Hellenic Dynamics, the Company announces that it has acquired an interest over GBP750,000 worth of shares in Hellenic Dynamics which the Company will receive as part of the proposed listing of Hellenic Dynamics.

Hellenic Dynamics has recently announced plans to list on the London Stock Exchange through a reverse take-over of an AIM-listed cash shell (the "Prospective RTO"). Kanabo understands that this Prospective RTO is well advanced with further announcements expected shortly.

The structure of Kanabo's acquisition of interest in Hellenic Dynamics is reflective of this near-term listing expectation and the desire of both parties to see this investment as part of a broader potential relationship between the two companies. The number of shares to be received by Kanabo will be calculated at the time of the Prospective RTO to ensure that the Kanabo investment will be de-facto made at a minimum 30% discount to the Prospective RTO listing price.

Avihu Tamir, CEO of Kanabo commented: "The MoU with Hellenic Dynamics and the subsequent investment is part of Kanabo's strategy to quickly grow its core business whilst pursuing complementary, synergistic, acquisitions and investments in the medical cannabis space, leveraging our position as a quoted company. We welcome the enthusiastic support of investors for our approach."

Davinder Rai, Vice President of Hellenic Dynamics, commented: "This agreement and investment in the business underscores the quality and scale of our specialist cultivation ambitions. We look forward to working closely with Kanabo and this deal highlights the demand and growth opportunity for Hellenic Dynamics in the European medical cannabis market."

For further information, please visit http://www.kanabogroup.com/ or contact the following:

Kanabo Group Plc

Tel: +(972)52-3173-633

press@kanabogroup.com

Meirav Horn

Peterhouse Capital Limited (Financial Adviser)

Tel: +44 (0)20 7469 0930

Eran Zucker / Guy Miller / Allie Feuerlein

Peterhouse Capital Limited (Corporate Broker)

Lucy Williams / Charles Goodfellow

About Kanabo

Kanabo aims to be an industry leader in product development and commercialisation of both cannabis-derived products for medical patients and THC-free products for CBD consumers. The company develops high-quality medical cannabis extract formulas, medical device vaporisers, and other innovative delivery methods. Validation activities are conducted at Kanabo's research lab at the Weizmann Science Park in Israel. With a primary focus on the German and UK Markets, Kanabo has already begun penetrating the European Market, and is positioned to scale up to meet growing market demand and projected sales. Currently, Kanabo is selling its line of CBD formulas for inhalation in the UK and Germany and has agreements with distributors in the pharmaceutical and OTC sectors already in place.

About Hellenic Dynamics

Hellenic Dynamics's main objective is to cultivate, produce, and extract tetrahydrocannabinol ("THC") dominant strains of dried medical cannabis flowers and flower extracts. These will be cultivated in its 200,000 square meter facility located near Kilkis in Northern Greece and are intended for export into the emerging medical cannabis market in Europe. The first medical cannabis flowers are expected to be cultivated in Q3 2021 with commercial sales expected to occur in Q4 2021. The Company's strategy is to then expand its total cultivation area in phases, in line with European demand. Additionally, the Board anticipates that further distribution lines into other European markets will begin in early 2022.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

STRFLFFAEDIVFIL

(END) Dow Jones Newswires

May 24, 2021 02:00 ET (06:00 GMT)

1 Year Spinnaker Opportunities Chart

1 Year Spinnaker Opportunities Chart

1 Month Spinnaker Opportunities Chart

1 Month Spinnaker Opportunities Chart
ADVFN Advertorial
Your Recent History
LSE
SOP
Spinnaker ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210729 02:29:40